Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice

Abstract

Purpose

Aprepitant and its parenteral formulation fosaprepitant are widely used for the prevention of chemotherapy-induced nausea and vomiting. Aprepitant exerts modest inhibitory effect on CYP3A4 and modest inductive effect on CYP2C9 substrates such as some antineoplastics and multiple other medications. This article is aimed to provide pharmacists and other healthcare professionals with an updated summary of drug–drug interactions of aprepitant/fosaprepitant and implications for clinical practice.

Method

We reviewed publications reporting drug–drug interactions between aprepitant/fosaprepitant and other medications.

Results

Coadministration of aprepitant with antineoplastics or opiods may result in significant elevations in the serum levels of the agents metabolized via CYP3A4, with the best documentation for cyclophosphamide, ifosfamide, erlotinib and oxycodone. These alterations did not translate into adverse outcomes and/or necessitate dosing adjustments. The levels of warfarin were significantly decreased by aprepitant requiring prolonged monitoring after discontinuation of aprepitant. Among direct oral anticoagulants, a theoretical interaction between aprepitant and rivaroxaban or apixaban exists. Interactions between aprepitant and quetiapine or diltiazem or sirolimus required dose reductions to avoid adverse outcomes. The intravenous route had a weaker inhibitory effect on CYP3A4 than the oral pathway.

Conclusion

The evidence on drug interactions of aprepitant with other medications is limited, and the impact on therapeutic outcomes remains to be determined. The intravenous regimen may be a preferred option. As utilization of aprepitant is expanding, practitioners and patients need to be educated about the potential for drug interactions and a need for careful monitoring of patients concurrently receiving aprepitant and CYP2C9 or CYP3A4 substrates, especially those with a narrow therapeutic window.

Keywords

Aprepitant fosaprepitant drug interactions cytochrome P450 enzyme system

Get full access to this article

View all access options for this article.

References

Herrstedt

. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 2008; 5: 32–43.

Hesketh

Kris

Grunberg

. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103–109.

National Comprehensive Cancer Network. Antiemesis (Version 1.2015), www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf (2015, accessed 15 May 2015).

Roila

Herrstedt

Aapro

. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010; 21(Suppl 5): v232–v243.

Basch

Hesketh

Kris

. Antiemetics: American society of clinical oncology clinical practice guideline update. J Oncol Pract 2011; 7: 395–398.

Merck & Co. Inc. Emend (aprepitant) (package insert), www.merck.com/product/usa/pi_circulars/e/emend/emend_pi.pdf (2015, accessed 21 November 2015).

Merck and Co. Inc. Emend (fosaprepitant) (package insert), www.merck.com/product/usa/pi_circulars/e/emend_iv/emend_iv_pi.pdf (2014, accessed 21 November 2015).

Aapro

Walko

. Aprepitant: drug-drug interactions in perspective. Ann Oncol 2010; 21: 2316–2323.

Merck & Co. Inc. United States Securities and Exchange Commission, www.sec.gov/Archives/edgar/data/64978/000095012305003003/y06253e10vk.htm (2005, accessed 10 September 2015).

10.

Mir

Blanchet

Goldwasser

. More on aprepitant for erlotinib-induced pruritus. N Engl J Med 2011; 364: 487–487.

11.

Mir

Coriat

. Aprepitant for pruritus: drug-drug interactions matter. Lancet Oncol 2012; 13: 964–965.

12.

Leveque

. Aprepitant for erlotinib-induced pruritus. N Engl J Med 2010; 363: 1680–1681. , author reply 1681.

13.

Taylor P. Merck plans expanded filing for Emend this year, www.pmlive.com/pharma_news/merck_plans_expanded_filing_for_emend_this_year_768501 (2015, accessed 10 July 2015).

14.

Micromedex® Healthcare Series. Thomson Micromedex, www.micromedexsolutions.com (2015, accessed 15 June 2015).

15.

Hale

Mills

MacCoss

. Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J Med Chem 1998; 41: 4607–4614.

16.

Parrott

Lukacova

Fraczkiewicz

. Predicting pharmacokinetics of drugs using physiologically based modeling – application to food effects. AAPS J 2009; 11: 45–53.

17.

Dando

Perry

. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2004; 64: 777–794.

18.

Sanchez

Wang

Newton

. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 2004; 32: 1287–1292.

19.

Marbury

Ngo

Shadle

. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. J Clin Pharmacol 2011; 51: 1712–1720.

20.

Majumdar

McCrea

Panebianco

. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 2003; 74: 150–156.

21.

Shadle

Lee

Majumdar

. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 2004; 44: 215–223.

22.

Depre

Van Hecken

Oeyen

. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 2005; 61: 341–346.

23.

Feuring

Lee

Orlowski

. Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects. J Clin Pharmacol 2003; 43: 912–917.

24.

Egerer

Eisenlohr

Gronkowski

. The NK(1) receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Br J Clin Pharmacol 2010; 70: 903–907.

25.

Bergman

Marbury

Fosbinder

. Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant. Clin Pharmacokinet 2005; 44: 637–647.

26.

Zhang

JTQ

Zhou

S-F

. Clinical pharmacology of cyclophosphamide and ifosphamide. Curr Drug Ther 2006; 1: 55–84.

27.

De Jonge

Huitema

Holtkamp

. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 2005; 56: 370–378.

28.

Bubalo

Cherala

McCune

. Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. J Clin Pharmacol 2012; 52: 586–594.

29.

Walko

Combest

Spasojevic

. The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 2012; 69: 1189–1196.

30.

Durand

Gourmel

Mir

. Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy. Ann Oncol 2007; 18: 808–809.

31.

Jarkowski

. Possible contribution of aprepitant to ifosfamide-induced neurotoxicity. Am J Health Syst Pharm 2008; 65: 2229–2231.

32.

Shindorf

Manahan

Geisler

. The interaction of ifosfamide and aprepitant in gynecologic malignancies. Gynecol Oncol Case Rep 2013; 6: 34–35.

33.

Sejourne

Noal

Boone

. Two cases of fatal encephalopathy related to Ifosfamide: an adverse role of aprepitant? Case Rep Oncol 2014; 7: 669–672.

34.

Howell

Szabatura

Hatfield Seung

. Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant. J Oncol Pharm Pract 2008; 14: 157–162.

35.

Yuen

. Aprepitant-associated ifosfamide neurotoxicity. J Oncol Pharm Pract 2010; 16: 137–138.

36.

Szabatura

Cirrone

Harris

. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. J Oncol Pharm Pract 2015; 21: 188–193.

37.

Pfizer Inc. Adriamycin (package insert), http://labeling.pfizer.com/ShowLabeling.aspx?id=530 (2014, accessed 21 November 2015).

38.

Bristol Myers Squibb. Etopophos: highlights of prescribing information, http://packageinserts.bms.com/pi/pi_etopophos.pdf (2014, accessed21 November 2015).

39.

Sarantopoulos

Mita

Wade

. Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel. Cancer Chemother Pharmacol 2014; 74: 1113–1124.

40.

Kaneta

Fujita

Akiyama

. No pharmacokinetic alteration of docetaxel following coadministration of aprepitant 3 h before docetaxel infusion. Cancer Chemother Pharmacol 2014; 74: 539–547.

41.

Loos

De Wit

Freedman

. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 2007; 59: 407–412.

42.

Van Leeuwen

Van Gelder

Mathijssen

. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 2014; 15: e315–e326.

43.

Pfizer Inc. Xalkori (package insert), http://labeling.pfizer.com/showlabeling.aspx?id=676 (2015, accessed 21 November 2015).

44.

Novartis Pharmaceuticals. Zykadia (package insert), http://www.pharma.us.novartis.com/product/pi/pdf/zykadia.pdf (2015, accessed 21 November 2015).

45.

Fujiwara

Toyoda

Chayahara

. Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. PloS One 2014; 9: e104215–e104215.

46.

Ohno

Yamada

Yamaguchi

. Persistent drug interaction between aprepitant and warfarin in patients receiving anticancer chemotherapy. Int J Clin Pharm 2014; 36: 1134–1137.

47.

Bristol-Myers Squibb Company. Coumadin (package insert), http://packageinserts.bms.com/pi/pi_coumadin.pdf (2011, accessed 21 November 2015).

48.

Jannsen Pharmaceuticals Inc. Xarelto: highlights of prescribing information, www.xareltohcp.com/shared/product/xarelto/prescribing-information.pdf (2015, accessed 21 November 2015).

49.

Bristol-Myers Squibb Company and Pfizer Inc. Apixaban (package insert), http://packageinserts.bms.com/pi/pi_eliquis.pdf (2015, accessed 21 November 2015).

50.

Kalabalik

Rattinger

Sullivan

. Use of non-vitamin K antagonist oral anticoagulants in special patient populations with nonvalvular atrial fibrillation: a review of the literature and application to clinical practice. Drugs 2015; 75: 979–998.

51.

Daiichi Sankyo. Savaysa (package insert), http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true (2015, accessed 21 November 2015).

52.

Boehringer Ingelheim Pharmaceuticals Inc. Pradaxa (package insert), http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf (2015, accessed 21 November 2015).

53.

Verwimp-Hoeks

van Herpen

Burger

. Aprepitant quetiapine: a clinically significant drug interaction in a patient treated for head and neck cancer. Ann Oncol 2012; 23: 801–802.

54.

Gilead Sciences Inc. Ranexa (package insert), www.gilead.com/∼/media/files/pdfs/medicines/cardiovascular/ranexa/ranexa_pi.pdf (2013, accessed 21 November 2015).

55.

Shayani

Palmer

Stiller

. Aprepitant (Emend) significantly increases sirolimus levels in patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transplant 2012; 47: 291–293.

56.

Ibrahim

Abidi

Ayash

. Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation. J Oncol Pharm Pract 2008; 14: 113–121.

57.

Stoch

Gargano

Valentine

. Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. Cancer Chemother Pharmacol 2011; 67: 1313–1321.

58.

Maie

Okoshi

Takaiwa

. Aprepitant does not alter prednisolone pharmacokinetics in patients treated with R-CHOP. Ann Oncology 2014; 25: 298–299.

59.

. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer 2007; 17: 739–763.

60.

Actelion Pharmaceuticals US Inc. Tracleer (package insert), www.tracleer.com/docs/Tracleer_Full_Prescribing_Information.pdf (2015, accessed 21 November 2015).

61.

Takeda Pharmaceuticals Inc. Colcrys (package insert), http://general.takedapharm.com/content/file.aspx?applicationcode=9D47C788-2804-4E6D-A831-1E0C0A7653B8&filetypecode=COLCRYSPI&cacheRandomizer=d282f268-6013-47a3-8813-39aa21f6aaae (2012, accessed 21 November 2015).

62.

Majumdar

Yan

Selverian

. Effect of aprepitant on the pharmacokinetics of intravenous midazolam. J Clin Pharmacol 2007; 47: 744–750.

63.

Merck Sharp & Dohme Corp. Belsomra (package insert), www.merck.com/product/usa/pi_circulars/b/belsomra/belsomra_pi.pdf (2014, accessed 21 November 2015).